Counseling the at risk patient in the BRCA1 and BRCA2 Era

Obstetrics and Gynecology Clinics of North America

Volumn 29, Issue 2, 2002, Pages 341-366

  Barnes Kedar, Inbal M ^a   Plon, Sharon E ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MC 3 3320 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; GENETIC COUNSELING; HIGH RISK PATIENT; HUMAN; MUTATION; OVARY CANCER; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; BREAST TUMOR; FEMALE; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HETEROZYGOTE; METHODOLOGY; OVARY TUMOR; PATIENT EDUCATION; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HETEROZYGOTE; HUMAN; OVARIAN NEOPLASMS; PATIENT EDUCATION; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; HUMANS;

EID: 0036287344     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8545(01)00004-3     Document Type: Review

References (94)

1. Isolation of BRCA1, the 17q-linked breast and ovarian cancer susceptibility gene
2. Identification of the breast cancer susceptibility gene BRCA2
3. Women's receptivity to testing for a genetic susceptibility to breast cancer
4. Linkage of early-onset familial breast cancer to chromosome 17q21
5. BRCA1, BRCA2, and DNA damage response: Collision or collusion?
6. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations
7. BRCA1 gene mutations in sporadic ovarian carcinomas: Detection by PCR and reverse allele-specific oligonucleotide hybridization
8. Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene
9. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals
10. The carrier frequency of the BRCA2 617delT mutation among Ashkenazi Jewish individuals is approximately 1%
11. A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families
12. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients
13. High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients
14. Cancer risks in BRCA2 mutation carriers. The breast cancer linkage consortium
15. Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer
16. Mutation analysis in the BRCA2 gene in primary breast cancers
17. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer
18. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2
19. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening
20. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families
21. Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions
22. Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing
23. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases
24. BRCA1 mutations and breast cancer in the general population: Analyses in women before age 35 years and in women before age 45 years with first-degree family history
25. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer
26. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families
27. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer
28. BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers
29. Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer
30. Low penetrance genes associated with increased risk for breast cancer
31. Breast and ovarian cancer incidence in BRCA1-mutation carriers
32. Risks of cancer in BRCA1-mutations carriers. Breast cancer linkage consortium
33. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews
34. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients
35. BRCA-associated breast cancer in young women
36. Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer
37. BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease
38. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population
39. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13
40. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene
41. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers
42. Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors
43. A genetic epidemiological study of carcinoma of the fallopian tube
44. The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer
45. Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men
46. No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer
47. Breast cancer genetics: What we know and what we need
48. Multiple primary cancers in families with Li-Fraumeni syndrome
49. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome
50. Phenotypic findings of Cowden syndrome and Bannayan-Zonana syndrome in a family associated with a single germline mutation in PTEN
51. An update on Lynch syndrome
52. Predisposition genetic testing for late-onset disorders in adults. A position paper of the National Society of Genetic Counselors
53. Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent
54. Genetic testing for cancer susceptibility, Adopted on February 20, 1996
55. Familial posterior fossa brain tumors of infancy secondary to germline mutation of the hSNF5 gene
56. Statement of the American Society of Human Genetics on genetic testing for breast and ovarian cancer predisposition
57. Breast - Ovarian cancer screening
58. An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling
59. Evaluation of the needs of male carriers of mutations in BRCA1 or BRCA2 who have undergone genetic counseling
60. Screening for 185delAG in the Ashkenazim
61. Effects of individual breast cancer risk counseling: A randomized trial
62. Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age
63. Psychologic aspects of cancer genetic testing - A research update for clinicians
64. Psychological distress and surveillance behaviors of women with a family history of breast cancer
65. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually
66. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction
67. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2
68. A descriptive study of BRCA1 testing and reactions to disclosure of test results
69. Insurance underwriting in the genetic era
70. Psychological responses to BRCA1 mutation testing: Preliminary findings
71. Professional disclosure of familial genetic information
72. 'Other' breast cancer susceptibility genes: Searching for more holy grail
73. What you don't know can hurt you: Adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing
74. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing
75. Mammography behavior after receiying a negative BRCA1 mutation test result in the Ashkenazim: A community-based study
76. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing
77. Clinical options for women at high risk for breast cancer
78. Variability and accuracy in mammographic interpretation using the American College of Radiology Breast Imaging Reporting and Data System
79. Recommendations for follow-up care of individuals with an inherited predisposition to cancer: II. BRCA1 and BRCA2
80. Doppler sonography in breast pathology
81. The role of ultrasound in the diagnosis of breast cancer
82. MR imaging of the breast
83. Magnetic resonance imaging of breast cancer: Clinical indications and breast MRI reporting system
84. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: Preliminary results
85. First experiences in screening women at high risk for breast cancer with MR imaging
86. MR imaging: Its current and potential utility in the diagnosis and management of breast cancer
87. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer
88. Tamoxifen and risk of contralateral breast cancer in BRCA1 riers: A case-control study
89. Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy
90. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers
91. Ovarian cancer risk reduction after bilateral prophylactic oophorectomy (BPO) in BRCA1 and BRCA2 mutation carriers
92. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry
93. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
94. Tamoxifen, raloxifene, and the prevention of breast cancer